WuXi AppTec Posts Stellar Q3 2022 Results with 209% Profit Surge
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its Q3 2022 financial...
OriginCell’s CAR-T Therapy Receives FDA Orphan Drug Designation for Multiple Myeloma
Shanghai-based tumor immunotherapy specialist OriginCell Therapeutics has announced that its investigational autologous chimeric antigen receptor...
Novartis Q3 Revenues Rise 4% YOY; China Sales Expand Despite COVID Lockdowns
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported a 4% year-on-year (YOY) increase in global...
ImmVira Secures Series C+ Financing to Advance Oncolytic Virus and Exosome Programs
China-based biotech ImmVira has successfully secured its Series C+ financing, entering into agreements with a...
Ascentage Pharma Files for Phase Ib/II Study of Bcl-2 Inhibitor in Systemic Lupus Erythematosus
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the submission of a clinical filing with the...
Shanghai Henlius’ PD-1 Inhibitor Serplulimab Gains Australian Clearance for Phase III Study
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving regulatory clearance in Australia to...
ArieMedi Secures Series A+ Financing to Expand Precision Navigation Solutions
ArieMedi Medical Science, a leading precision navigation solutions provider based in Beijing, has announced the...
ClinBrain Raises RMB 200 Million in Series C Financing to Boost Medical Big Data
Shanghai-based ClinBrain, a leading clinical data repository (CDR) and medical big data services provider, has...
Covis Pharma’s COPD Therapies Show Positive Results in Phase III AVANT Trial
Luxembourg-based Covis Pharma Group has released positive topline data from its Phase III AVANT trial,...
Huadong Medicine Reports 10.4% Revenue Growth in Q3 2022
Huadong Medicine Co., Ltd (SHE: 000963) has published its Q3 2022 financial report, revealing robust...
CSPC Receives CDE Approval for Generic Version of Pfizer’s Xeljanz
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received market...
Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion
China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to...
BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda
China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has...
Shandong Branden Medical Devices Files for IPO on STAR Board to Raise RMB 760M
China-based Shandong Branden Medical Devices Co., Ltd has filed for an initial public offering (IPO)...
Gan & Lee Pharmaceuticals Plans RMB 814M Private Placement for Working Capital
China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced plans to raise up to RMB...
Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D
Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of...
Daiichi Sankyo Initiates Global Phase II Study of DS7300 for Small-Cell Lung Cancer
Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced the first patient dosing in a global...
Abbisko’s ABSK021 Gets CDE Approval for Phase III Study in Giant Cell Tumor of Tendon Sheath
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...
Livzon Launches National Rollout of COVID-19 Vaccine V-01 in China
China-based Livzon Pharmaceutical Group (HKG: 1513) has announced the national promotion of its recombinant novel...
Venmedtech Raises Series B+ Funding for Iliac Vein Stent and Product R&D
Venmedtech, a Suzhou-based one-stop intravenous therapy product platform, has reportedly raised “tens of millions” of...